July 29, 2010 in Melanoma news
Antigenics Inc. reported today its results for the quarter ended June 30, 2010. The company incurred a net loss attributable to common stockholders of $5.2 million, or $0.05 per share, basic and diluted, for the second quarter of 2010, compared with a net loss attributable to common stockholders of $12.3 million, or $0.17 per share, basic and ...